MX2020003995A - Nuevas moleculas de acido nucleico artificiales. - Google Patents

Nuevas moleculas de acido nucleico artificiales.

Info

Publication number
MX2020003995A
MX2020003995A MX2020003995A MX2020003995A MX2020003995A MX 2020003995 A MX2020003995 A MX 2020003995A MX 2020003995 A MX2020003995 A MX 2020003995A MX 2020003995 A MX2020003995 A MX 2020003995A MX 2020003995 A MX2020003995 A MX 2020003995A
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid molecules
artificial nucleic
novel artificial
novel
Prior art date
Application number
MX2020003995A
Other languages
English (en)
Inventor
Thomas Schlake
Andreas Thess
Moritz Thran
Frédéric Chevessier-Tünnesen
Marion Pönisch
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/057552 external-priority patent/WO2018172556A1/en
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of MX2020003995A publication Critical patent/MX2020003995A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Abstract

La presente invención proporciona moléculas de ácido nucleico artificiales que comprenden nuevas combinaciones de elementos de la región no traducida (UTR) 5' y 3'. Las moléculas de ácido nucleico de la invención se caracterizan preferiblemente por una mayor eficacia de expresión de las regiones codificantes unidas operativamente a dichos elementos UTR. Los ácidos nucleicos artificiales pueden usarse para el tratamiento o la profilaxis de diversas enfermedades. La invención proporciona además composiciones (farmacéuticas), vacunas y kits que comprenden dichas moléculas artificiales de ácido nucleico. Además, se proporcionan métodos in vitro para preparar las moléculas de ácido nucleico artificiales según la invención.
MX2020003995A 2017-10-19 2018-10-17 Nuevas moleculas de acido nucleico artificiales. MX2020003995A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2017076741 2017-10-19
EP2017076775 2017-10-19
PCT/EP2018/057552 WO2018172556A1 (en) 2017-03-24 2018-03-23 Nucleic acids encoding crispr-associated proteins and uses thereof
EP2018076185 2018-09-26
PCT/EP2018/078453 WO2019077001A1 (en) 2017-10-19 2018-10-17 NEW ARTIFICIAL NUCLEIC ACID MOLECULES

Publications (1)

Publication Number Publication Date
MX2020003995A true MX2020003995A (es) 2020-07-22

Family

ID=66173912

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003995A MX2020003995A (es) 2017-10-19 2018-10-17 Nuevas moleculas de acido nucleico artificiales.

Country Status (13)

Country Link
US (1) US20220233568A1 (es)
EP (1) EP3697912A1 (es)
JP (2) JP2021501572A (es)
KR (1) KR20200071081A (es)
CN (1) CN111630173A (es)
AU (1) AU2018351481A1 (es)
BR (1) BR112020004351A2 (es)
CA (1) CA3073634A1 (es)
IL (1) IL272850A (es)
MX (1) MX2020003995A (es)
RU (1) RU2020115287A (es)
SG (1) SG11202002186VA (es)
WO (1) WO2019077001A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014220957A1 (en) 2013-02-22 2015-07-30 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
DK3319622T3 (da) 2015-12-22 2020-05-04 Curevac Ag Fremgangsmåde til fremstilling af rna-molekylesammensætninger
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
SG10202110491PA (en) 2017-03-24 2021-11-29 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
EP3707271A1 (en) 2017-11-08 2020-09-16 CureVac AG Rna sequence adaptation
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
US11525158B2 (en) 2017-12-21 2022-12-13 CureVac SE Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
CN112292395A (zh) * 2018-04-17 2021-01-29 库瑞瓦格股份公司 用于疫苗接种的新型rsv rna分子和组合物
CN110241116B (zh) * 2019-05-21 2023-02-07 中国医学科学院放射医学研究所 一种环状rna及在促进dna损伤修复中的应用
EP3986452A1 (en) 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
CN114729369A (zh) * 2019-08-29 2022-07-08 苏黎世大学 最小mRNA及其用途
CN110592223B (zh) * 2019-10-31 2022-10-25 中南大学湘雅三医院 一种NSCLC的诊断和预后标记物hsa_circRNA_012515的应用
CN112759652B (zh) * 2019-11-01 2022-09-20 北京华夏清医治疗科技有限公司 一种嵌合抗原受体及其应用
US20230008266A1 (en) * 2019-11-07 2023-01-12 Icahn School Of Medicine At Mount Sinai Synthetic modified rna and uses thereof
CN111041025B (zh) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
BR112022011803A2 (pt) 2019-12-20 2022-08-30 Curevac Ag Nanopartículas de lipídio para entrega de ácidos nucleicos
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
IL293571A (en) 2020-02-04 2022-08-01 Curevac Ag Corona virus vaccine
JP2023512707A (ja) * 2020-02-05 2023-03-28 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ｒｎａ負荷ナノ粒子およびがんの治療のためのそれらの使用
AU2021247163A1 (en) * 2020-04-01 2022-10-20 University Of Florida Research Foundation, Incorporated Multilamellar RNA nanoparticle vaccine against SARS-CoV-2
CN111413498B (zh) * 2020-04-08 2023-08-04 复旦大学附属中山医院 一种肝细胞肝癌的自身抗体7-AAb检测panel及其应用
AU2021279312A1 (en) 2020-05-29 2022-12-15 CureVac SE Nucleic acid based combination vaccines
CN111744019B (zh) * 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
US20230279408A1 (en) * 2020-08-07 2023-09-07 The Hong Kong University Of Science And Technology Compositions and methods for increasing protein expression
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
EP4225448A1 (en) * 2020-10-09 2023-08-16 Duke University Novel targets for reactivation of prader-willi syndrome-associated genes
CN112280750B (zh) * 2020-10-22 2022-11-01 山东农业大学 具有跨种传播能力的新型鹅星状病毒及其应用
CN112526127B (zh) * 2020-10-28 2022-12-06 四川大学华西医院 一种破伤风抗原的检测方法及其应用
EP4267178A1 (en) 2020-12-22 2023-11-01 CureVac SE Rna vaccine against sars-cov-2 variants
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
CN112574997B (zh) * 2021-01-17 2023-07-21 楷拓生物科技(苏州)有限公司 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用
US20240102065A1 (en) 2021-01-27 2024-03-28 CureVac SE Method of reducing the immunostimulatory properties of in vitro transcribed rna
EP4291571A2 (en) * 2021-02-12 2023-12-20 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Activity-inducible fusion proteins having a heat shock protein 90 binding domain
CN117377491A (zh) 2021-03-26 2024-01-09 葛兰素史克生物有限公司 免疫原性组合物
EP4312988A2 (en) 2021-03-31 2024-02-07 CureVac SE Syringes containing pharmaceutical compositions comprising rna
CN113341152B (zh) * 2021-04-27 2022-04-26 华南农业大学 Rps9蛋白在食蟹猴超数排卵良好应答预测中的应用
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
CA3171750A1 (en) 2021-07-30 2023-02-02 Tim SONNTAG Mrnas for treatment or prophylaxis of liver diseases
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
CN115606550B (zh) * 2022-10-28 2024-01-12 陆华 一种自身免疫性甲状腺炎诱导的卵巢储备功能低下动物模型的构建方法
CN116240175B (zh) * 2023-02-28 2024-02-23 武汉科技大学 一种嵌合抗hiv广谱中和抗体外泌体的制备方法以及在抗hiv感染中的应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102286077A (zh) 1996-06-14 2011-12-21 明治乳业株式会社 T细胞表位肽
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
AU6620300A (en) 1999-08-03 2001-02-19 Ohio State University, The Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
EP1800697B1 (de) 2001-06-05 2010-04-14 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
EP2046954A2 (en) 2006-07-31 2009-04-15 Curevac GmbH NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
AU2007283731B2 (en) 2006-08-11 2013-10-24 Katholieke Universiteit Leuven Immunogenic peptides and their use in immune disorders
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
EP2548960B1 (en) 2008-01-31 2018-01-31 CureVac AG Nucleic acids comprising formula (nugixmgnv)a and derivatives thereof as an immunostimulating agents/adjuvant
ES2638448T3 (es) 2008-04-15 2017-10-20 Protiva Biotherapeutics Inc. Novedosas formulaciones de lípidos para la administración de ácidos nucleicos
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
CA3006395C (en) 2008-11-07 2022-05-31 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
KR20210158864A (ko) 2008-11-10 2021-12-31 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
WO2010087791A1 (en) 2009-01-27 2010-08-05 Utc Power Corporation Distributively cooled, integrated water-gas shift reactor and vaporizer
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
EP3097908A1 (en) 2009-05-05 2016-11-30 Arbutus Biopharma Corporation Lipid compositions
PT3431076T (pt) 2009-06-10 2021-10-26 Arbutus Biopharma Corp Formulação lipídica melhorada
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CN104922071A (zh) 2010-04-09 2015-09-23 帕西拉制药有限公司 用于配制大直径合成膜囊泡的方法
EP3254672A1 (en) 2010-06-03 2017-12-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
CN108042799A (zh) 2010-07-06 2018-05-18 诺华股份有限公司 阳离子水包油乳液
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
EP2955230A1 (en) 2010-07-30 2015-12-16 CureVac AG Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012031046A2 (en) 2010-08-31 2012-03-08 Novartis Ag Lipids suitable for liposomal delivery of protein-coding rna
SI4008357T1 (sl) 2010-08-31 2023-04-28 Glaxosmithkline Biologicals Sa Mali liposomi za dostavo imunogen-kodirajoče RNA
HRP20230185T8 (hr) 2010-08-31 2023-07-21 Glaxosmithkline Biologicals Sa Pegilirani liposomi za isporuku rna koja kodira imunogen
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
BR112014000236A2 (pt) 2011-07-06 2017-02-14 Novartis Ag lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
CA2859452C (en) * 2012-03-27 2021-12-21 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression
RU2660565C2 (ru) * 2012-03-27 2018-07-06 Кьюрвак Аг Молекулы искусственной нуклеиновой кислоты, содержащие 5'utr гена top
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
AU2014220957A1 (en) 2013-02-22 2015-07-30 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
SG10201801431TA (en) 2013-08-21 2018-04-27 Curevac Ag Respiratory syncytial virus (rsv) vaccine
WO2015024666A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating lung cancer
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
KR20160043103A (ko) 2013-08-21 2016-04-20 큐어백 아게 전립선암 치료를 위한 조성물 및 백신
DK3090053T3 (en) * 2013-12-30 2019-02-25 Curevac Ag Artificial nucleic acid molecules
US10307472B2 (en) 2014-03-12 2019-06-04 Curevac Ag Combination of vaccination and OX40 agonists
EP3129050A2 (en) 2014-04-01 2017-02-15 CureVac AG Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2016097065A1 (en) 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
SG10201906673WA (en) * 2014-12-30 2019-09-27 Curevac Ag Artificial nucleic acid molecules
BR112017018368B1 (pt) 2015-04-22 2022-08-02 Curevac Ag Composição contendo rna para uso no tratamento ou profilaxia de doenças tumorais e/ou cancerosas, e uso de um rna para a preparação da composição
US20190017100A1 (en) * 2015-07-01 2019-01-17 Curevac Ag Method for analysis of an rna molecule
MX2018001040A (es) * 2015-08-28 2018-06-15 Curevac Ag Moleculas de acido nucleico artificiales.
EP3374504A2 (en) 2015-11-09 2018-09-19 CureVac AG Optimized nucleic acid molecules
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
DK3319622T3 (da) 2015-12-22 2020-05-04 Curevac Ag Fremgangsmåde til fremstilling af rna-molekylesammensætninger
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
WO2018104540A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
SG10202110491PA (en) * 2017-03-24 2021-11-29 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof

Also Published As

Publication number Publication date
KR20200071081A (ko) 2020-06-18
RU2020115287A3 (es) 2022-02-28
EP3697912A1 (en) 2020-08-26
AU2018351481A1 (en) 2020-03-12
CA3073634A1 (en) 2019-04-25
US20220233568A1 (en) 2022-07-28
BR112020004351A2 (pt) 2020-09-08
JP2021501572A (ja) 2021-01-21
CN111630173A (zh) 2020-09-04
RU2020115287A (ru) 2021-11-19
SG11202002186VA (en) 2020-05-28
JP2024012523A (ja) 2024-01-30
WO2019077001A1 (en) 2019-04-25
IL272850A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
MX2020003995A (es) Nuevas moleculas de acido nucleico artificiales.
SG11201911430PA (en) Novel nucleic acid molecules
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
MX2020004698A (es) Exosomas que comprenden agentes terapeuticos de arn.
MX2020004287A (es) Procesamiento de biomasa.
PH12016501763A1 (en) Multispecific antibodies
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
SG10201913629VA (en) Artificial nucleic acid molecules
SG11201704681QA (en) Artificial nucleic acid molecules
PL4023755T3 (pl) Sztuczne cząsteczki kwasu nukleinowego dla poprawy ekspresji białka
MX2020003760A (es) Formulaciones de niraparib.
MX2020004424A (es) Formulacion aerosolizable.
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2020012893A (es) Formulaciones de proteinas.
MX2020003649A (es) Elemento de seguridad optico.
MX2020004662A (es) Ajuste planificado del contorno mediante especificaciones correspondientes.
MX2020004045A (es) Molecula inhibidora del acido nucleico de la catenina beta.
MX2020004245A (es) Estabilizador mejorado para poliamidas.
MX2020003578A (es) Sal de edaravone.
MX2020002908A (es) Composicion acuosa de polimeros.
MX2016009774A (es) Ensayo biologico de peptidoglicanos.
MX2020003611A (es) Metodos de refuerzo del pozo.
MX2020003539A (es) Dispositivo de impulso.
MX2020003724A (es) Microscopio estereoscopico con un solo objetivo.
MX2020004664A (es) Dispositivo generador de humo mejorado.